Investigation Report on China's Loratadine Market, 2018-2022


Description
The incidences of common skin redness, itching and rashes and respiratory allergies are rising as China?s economy develops, the living environment and dietary structure change, and environmental pollution intensifies, which drives the growth of the antihistamine market. 
As a second-generation antihistamine, Loratadine is a common H1 receptor antagonist used to relieve the symptoms of allergic rhinitis, eye itching and burning sensation, and the symptoms and signs of chronic urticaria, pruritic skin diseases and other allergic skin diseases. It can quickly relieve nose and eye allergies. Moreover, Loratadine has a low affinity for the H1 receptor of the central nervous system, and thus has hardly any side effect on the nervous system. 
Developed by Schering-Plough which has been acquired by Bayer, Loratadine (trade name: Clarityne) was first launched in Belgium in 1988 and then sold in several European countries. In Apr. 1993, it was approved by the FDA to be marketed in the U.S. In Sept. 2002, it was launched in Japan. In November of the same year, the FDA approved Clarityne as a non-prescription drug. 
According to CRI, in Jun. 1993, imported Loratadine tablets were approved to be sold in China under the trade name Clarityne. In 2005, the CFDA approved Clarityne as a non-prescription drug for its excellent effect and long-tested safety. Many Chinese companies have launched generic Loratadine products in the dosage forms of oral tablets, capsules, granules, syrup and compound preparation. The market competition is fierce but the brand-name drug still has great advantages. In 2017, Shanghai Schering-Plough Pharmaceutical Co., Ltd. and Schering-Plough occupied about 65% market share by sales value. But the market share of the brand-name drug showed a downward trend. 
Loratadine has secured a place on the market by advantage of long-lasting and quick-acting effect and rare adverse reactions. However, with the increasing number of Loratadine manufacturers and intensifying competition on the market, the average price of Loratadine is declining. 
It is expected that as the incidences of allergic diseases continue to increase, China's Loratadine market will still have some growth potential in the next few years.

Topics Covered:
- Situation of allergic diseases in China
- Status of China's Loratadine market
- Competition on China's Loratadine market
- Prices of Loratadine in China
- Major factors influencing development of China's Loratadine market
- Prospect of China's Loratadine market from 2018 to 2022
Table of Contents
1 Relevant Concepts of Loratadine
1.1 Indications for Loratadine
1.2 Development of Loratadine in China
1.3 Governmental Approval of Loratadine in China

2 Sales of Loratadine in China, 2013-2017
2.1 Sales Value of Loratadine in China
2.1.1 Overall Sales Value
2.1.2 Sales Value by Region
2.2 Sales Volume of Loratadine  
2.2.1 Overall Sales Volume
2.2.2 Sales Volume by Region
2.3 Sales of Loratadine by Dosage Form in China, 2013-2017
2.3.1 Sales of Loratadine Tablets in China
2.3.2 Sales of Loratadine Capsules in China
2.3.3 Sales of Loratadine Granules in China
2.3.4 Sales of Loratadine Syrups in China

3 Analysis on Major Loratadine Manufacturers in China, 2013-2017
3.1 Analysis on Market Shares of Major Loratadine Manufacturers in China
3.1.1 Market Share by Sales Value
3.1.2 Market Share by Sales Volume
3.2 Shanghai Schering-Plough Pharmaceutical Co., Ltd. 
3.2.1 Enterprise Profile
3.2.2 Sales of Shanghai Schering-Plough Pharmaceutical Co., Ltd.'s Loratadine in China
3.3 Schering-Plough
3.3.1 Enterprise Profile
3.3.2 Sales of Schering Plough's Loratadine in China
3.4 Beijing SL Pharmaceutical Co., Ltd. 
3.4.1 Enterprise Profile
3.4.2 Sales of Beijing SL Pharmaceutical Co., Ltd.'s Loratadine in China
3.5 Venturepharm Pharmaceutical (Hainan) Co., Ltd. 
3.6 Jiangsu Hanchen Pharmaceutical Co., Ltd. 

4 Prices of Loratadine in China, 2017-2018
4.1 Shanghai Schering-Plough Pharmaceutical Co., Ltd. (Clarityne)
4.2 Schering-Plough (Clarityne)
4.3 Beijing SL Pharmaceutical Co., Ltd. (Leining)
4.4 Venturepharm Pharmaceutical Co., Ltd. (Baiweile)
4.5 Jiangsu Hanchen Pharmaceutical Co., Ltd. (Yibaizhi)

5 Prospect of China's Loratadine Market, 2018-2022
5.1 Major Factors Influencing Development of China's Loratadine Market
5.1.1 Favorable Factors
5.1.2 Unfavorable Factors
5.2 Forecast on Market Size
5.3 Forecast on Market Trend

Selected Charts
Chart Governmental Approval of Loratadine in China
Chart Sales Value of Loratadine in China, 2013-2017
Chart Sales Value of Loratadine in Parts of China, 2013-2017
Chart Sales Volume of Loratadine in China, 2013-2017
Chart Sales Volume of Loratadine in Parts of China, 2013-2017
Chart Sales Value of Loratadine Tablets in China, 2013-2017
Chart Sales Volume of Loratadine Tablets in China, 2013-2017
Chart Sales Value of Loratadine Capsules in China, 2013-2017
Chart Sales Value of Loratadine Granules in China, 2013-2017
Chart Market Share of Top 5 Loratadine Manufacturers by Sales Value in China, 2013-2017
Chart Profile of Shanghai Schering-Plough Pharmaceutical Co., Ltd. 
Chart Sales Value of Shanghai Schering-Plough Pharmaceutical Co., Ltd.'s Loratadine, 2013-2017
Chart Profile of Schering-Plough
Chart Sales Value of Schering-Plough's Loratadine in China, 2013-2017
Chart Sales Volume of Schering-Plough's Loratadine in China, 2013-2017
Chart Profile of Beijing SL Pharmaceutical Co., Ltd. 
Chart Sales Value of Beijing SL Pharmaceutical Co., Ltd.'s Loratadine, 2013-2017
Chart Sales Value of Venturepharm Pharmaceutical (Hainan) Co., Ltd.'s Loratadine, 2013-2017
Chart Sales Value of Jiangsu Hanchen Pharmaceutical Co., Ltd.'s Loratadine, 2013-2017
Chart Prices of Shanghai Schering-Plough Pharmaceutical Co., Ltd.'s Loratadine (Clarityne) in Parts of China, 2017-2018
Chart Prices of Schering-Plough's Loratadine (Clarityne) in Parts of China, 2017-2018
Chart Prices of Beijing SL Pharmaceutical Co., Ltd.'s Loratadine (Leining) in Parts of China, 2017-2018
Chart Prices of Venturepharm Pharmaceutical (Hainan) Co., Ltd.'s Loratadine (Baiweile) in Parts of China, 2017-2018
Chart Prices of Jiangsu Hanchen Pharmaceutical Co., Ltd.'s Loratadine (Yibaizhi) in Parts of China, 2017-2018
Chart Forecast on Sales Value of Loratadine in China, 2018-2022


Name*
Email ID*
Company*
Phone (With Country Code)*
What is/are your question(s)?:

Other Reports by China Research and Intelligence

Investigation Report on China's Finasteride Market, 2019-2023

Description The prostate is a male-specific gonadal organ. Benign prostatic hyperplasia (BPH) is the most common benign disease among the causes of urination disorder in middle-aged and elderly men. Epidemiologically, the incidence of BPH increases w...

Investigation Report on China's Prothrombin Complex Concentrate (PCC) Market, 2019-2023

Description Hemophilia is an X-linked recessive hemorrhagic disease. It is classified into hemophilia A, a deficiency in clotting factor VIII and hemophilia B, a deficiency in clotting factor IX. Both hemophilia A and hemophilia B are caused by gene ...

Investigation Report on China's Recombinant Human Thrombopoietin Market, 2019-2023

Description In recent years, the incidence of thrombopenia in China keeps increasing. Thrombopenia is often seen in hematologic diseases such as primary immune thrombopenia, leukemia and aplastic anemia as well as in connective tissue diseases, liver...

Investigation Report on China's Pegaspargase Market, 2019-2023

Description According to the data released by China?s National Health Commission in Oct. 2018, the incidence of childhood leukemia in Chinese children under 15 is about 4/100,000 to 5/100,000, and the number of childhood leukemia patients under 18 ol...

Investigation Report on China's Basiliximab Market, 2019-2023

Description In China, 10.80% or about 150 million people have chronic kidney disease, and over 3 million of them have end-stage renal disease, i.e. uremia. According to CRI, the incidence of chronic kidney disease in China stays at a high level in re...

New Pharmaceuticals and Healthcare Reports

Publisher: China Research and Intelligence